Cited by 316Neuroscience and Neuropharmacology ResearchAlzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.

NPTX2 and cognitive dysfunction in Alzheimer’s Disease

Open access

Xiao, Mei-Fang, Xu, Desheng, Craig, Michael T, Pelkey, Kenneth A, Chien, Chun-Che, Shi, Yang, Zhang, Juhong, Resnick, Susan, Pletnikova, Olga, Salmon, David, Brewer, James, Edland, Steven, Wegiel, Jerzy, Tycko, Benjamin, Savonenko, Alena, Reeves, Roger H, Troncoso, Juan C, McBain, Chris J, Galasko, Douglas, Worley, Paul F·2017·eLife

DOI 10.7554/elife.23798PMC PMC5404919

Open this paper in CoChat — free account

Abstract

Memory loss in Alzheimer’s disease (AD) is attributed to pervasive weakening and loss of synapses. Here, we present findings supporting a special role for excitatory synapses connecting pyramidal neurons of the hippocampus and cortex with fast-spiking parvalbumin (PV) interneurons that control network excitability and rhythmicity. Excitatory synapses on PV interneurons are dependent on the AMPA receptor subunit GluA4, which is regulated by presynaptic expression of the synaptogenic immediate early gene NPTX2 by pyramidal neurons. In a mouse model of AD amyloidosis, Nptx2-/- results in reduced GluA4 expression, disrupted rhythmicity, and increased pyramidal neuron excitability. Postmortem human AD cortex shows profound reductions of NPTX2 and coordinate reductions of GluA4. NPTX2 in human CSF is reduced in subjects with AD and shows robust correlations with cognitive performance and hippocampal volume. These findings implicate failure of adaptive control of pyramidal neuron-PV circuits as a pathophysiological mechanism contributing to cognitive failure in AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.7554/elife.23798

Cites

91 of 91 references verified0 citation errors · 0 not checkable

Statistics

Figure 1. NPTX2 levels are reduced in human postmortem AD brain and DS brain, but not in ASYMAD brain. (A,B,D and E) Representative western blot images (A) and quantification of NPTX2 (B), NPTX1 (D) and NPTXR (E) normalized to PSD95 in the frontopolar cortex (FPC), precuneus (PCU), occipital gyrus (OCC), middle frontal gyrus (MFG), middle temporal gyrus (MTG) and parietal gyrus (PAR) from controls and AD subjects. NPTX2 is down-regulated in all assayed brain regions of AD individuals. FPC: control, n = 7; AD, n = 8. PCU: control, n = 15; AD, n = 19. OCC: control, n = 7; AD, n = 7. MFG: control, n = 9; AD, n = 16. MTG: control, n = 10; AD, n = 18. PAR: control, n = 5; AD, n = 5. (C) Nptx2 mRNA is reduced in AD brain. FPC: control, n = 9; AD, n = 16. PCU: control, n = 7; AD, n = 6. (F,G) Western blot assays reveal no significant change of NPTX2 expression in MFG from subjects with asymptomatic AD (ASYMAD). Control, n = 8; ASYMAD, n = 10. (H, I) Western blot assays show significant reduction of NPTX2 in MFG of individuals with Down syndrome (DS). Control, n = 6; DS, n = 6. (J) Nptx2 mRNA is reduced in MFG of individuals with DS. Control, n = 5; DS, n = 5. *p<0.05, **p<0.01, ***p<0.001 by two-tailed t test. Data represent mean ± SEM. DOI: http://dx.doi.org/10.7554/eLife.23798.002CC BY · PubMed Central

Figure 1—figure supplement 1. Immediate early gene expression in human postmortem AD brain. (A) NPTX2 levels are reduced in human postmortem AD brain. Quantification of NPTX2, NPTX1 and NPTXR levels in Figure 1A with actin as reference protein. NPTX2 is down-regulated in all assayed brain regions of AD individuals when referenced to actin. Frontopolar cortex (FPC): control, n = 7; AD, n = 8. Precuneus (PCU): control, n = 15; AD, n = 19. Occipital gyrus (OCC): control, n = 7; AD, n = 7. Middle frontal gyrus (MFG): control, n = 9; AD, n = 16. Middle temporal gyrus (MTG): control, n = 10; AD, n = 18. Parietal gyrus (PAR): control, n = 5; AD, n = 5. (B) Egr1 and Arc expression in different brain regions of control and AD subjects. Western blots show that expression of Egr1 and Arc are not significantly altered in most tested brain areas from AD individuals. FPC: control, n = 7; AD, n = 8. PCU: control, n = 15; AD, n = 19. OCC: control, n = 7; AD, n = 7. MFG: control, n = 9; AD, n = 16. MTG: control, n = 10; AD, n = 18. PAR: control, n = 5; AD, n = 5. *p<0.05, **p<0.01, ***p<0.001 by two-tailed t test. Data represent mean ± SEM. DOI: http://dx.doi.org/10.7554/eLife.23798.006CC BY · PubMed Central

Figure 1—figure supplement 2. NPTX2 levels are reduced in human postmortem DS-AD brain. (A) Western blot assays show NPTX2 down-regulation in superior frontal gyrus (SFG) of individuals with Down syndrome and Alzheimer’s disease (DS-AD). Control, n = 8; DS-AD, n = 12. (B) Nptx2 mRNA is reduced in SFG of individuals with DS-AD. Control, n = 8; DS-AD, n = 12. *p<0.05, by two-tailed t test. Data represent mean ± SEM. See patients information in Figure 1—source data 3. DOI: http://dx.doi.org/10.7554/eLife.23798.007CC BY · PubMed Central

Figure 2. miRNAs dysregulation and NPTX2 down-regulation in AD brains. (A) Nptx2 pre-mRNA levels are identical in frontopolar cortex (FPC) of AD subjects and control. Control, n = 9; AD, n = 16. (B) microRNAs predicted to bind with Nptx2 3’UTR by TargetScan. (C) Taqman assays show miR-182 and miR-1271 are increased in FPC of AD individuals. Control, n = 9; AD, n = 16. *p<0.05, **p<0.01 by two-tailed t test. (D) miR-96, miR-152 and miR-182 are up-regulated in individuals with Down syndrome (DS). Triploid miR-155 served as positive control. Control, n = 14; DS, n = 18. *p<0.05, **p<0.01, ***p<0.001 by two-tailed t test. (E) miR-96, miR-182 and miR-1271 target the same sequence in Nptx2 3’UTR. (F–H) Cultured mouse cortical neurons are transduced with lentivirus expressing nontargeting miRNA (LV-NT) or miR-96, miR-1271 and miR-182. (F) Expression of miR-96, miR-1271 and miR-182 reduce NPTX2 protein level. (G) miR-96 reduces Nptx2 mRNA. (H) Nptx2 pre-mRNA is preserved by miR-96 and miR-1271 expression. n = 5 wells from three independent culture except n = 4 wells for LV-NT group in Figure 2G. *p<0.05, ***p<0.001 by nonparametric one way ANOVA with Tukey post hoc test. Data represent mean ± SEM. DOI: http://dx.doi.org/10.7554/eLife.23798.008CC BY · PubMed Central

Figure 2—figure supplement 1. Methylation of Nptx2 promoter in human brain. (A) Representative pyrosequencing traces show high methylation of Nptx2 promoter in pancreatic cell line AsPC1 cells, and low methylation in human brain. (B) Nptx2 promoter methylation in brains is not different between control and AD subjects. n = 8 per group. Two-tailed t test was performed. Data represent mean ± SEM. DOI: http://dx.doi.org/10.7554/eLife.23798.009CC BY · PubMed Central

Figure 2—figure supplement 2. Nptx2 mRNA is targeted by miRNAs that are upregulated in AD brain. (A) miR-1271 up-regulation correlates with reduced Nptx2 mRNA. Control, n = 9; AD, n = 16. Pearson correlation coefficient analysis was performed. (B,C) Assays of Nptx2 mRNA and miRNA in AD precuneus (PCU) region. (B) Nptx2 mRNA is reduced in PCU area of AD subjects with preserved Nptx2 pre-mRNA. Control, n = 7; AD, n = 6. (C) miR-152 and miR-182 are increased in AD PCU region compared with control. n = 7 per group. *p<0.05, **p<0.01, ***p<0.001 by two-tailed t test. (D) Nptx2 pre-mRNA is reduced in superior frontal gyrus (SFG) of subjects with Down syndrome. Control, n = 14; DS, n = 18. **p<0.01 by two-tailed t test. (E,F) miRNAs directly target Nptx2 3’UTR. (E) Wild-type (WT) or miR-binding site mutated (Mut) Nptx2 3’UTR is inserted downstream of a luciferase reporter. Mutated nucleotides are in red. (F) miRNA mimics are able to reduce the luciferase activity in HEK293 cells, and this effect is partially abolished by mutation of miRNA binding site on Nptx2 3’UTR. n = 9–16 wells. * miRNA mimic vs control RNA; # WT Nptx2 vs mutant Nptx2. Two-tailed t test. (G) Western blot assays show no significant changes of Gephyrin and Homer1, which are predicted targets of miR-1271, in human postmortem brain. Frontopolar cortex (FPC): control, n = 7; AD, n = 8. Precuneus gyrus (PCU): control, n = 15; AD, n = 18. (H) mRNA levels of Gephyrin and Homer1 in brain are not significantly altered in AD subjects. FPC: control, n = 9; AD, n = 16. PCU: control, n = 7; AD, n = 6. Data represent mean ± SEM. DOI: http://dx.doi.org/10.7554/eLife.23798.010CC BY · PubMed Central

Figure 3. Circuit Rhythmicity and GluA4 expression are disrupted in hAPP/Nptx2-/- mice. (A–D) Example extracellular field potentials (i) with hatched area shown on an expanded time base (ii) for WT (A), Nptx2-/- (B), hAPP (C), and hAPP/Nptx2-/- (D) mice. For hAPP/Nptx2-/- trace, grey trace in (ii) shows trace on expanded time base and the black trace shows expanded voltage axis to show gamma-like oscillations nested within population spikes. (E) Power spectra for WT, Nptx2-/-, hAPP, and hAPP/Nptx2-/- mice, taken from 400 s of recording, normalised to the power between 3 and 300 Hz. (F) The normalised power of gamma-like oscillations was significantly reduced in hAPP/Nptx2-/- mice (z-score; WT, 5.1 ± 0.73; Nptx2-/-, 3.8 ± 0.63; hAPP, 3.9 ± 0.79; hAPP/Nptx2-/-, 1.7 ± 0.68; p=0.0199, One-way ANOVA). **, p<0.01 vs WT, post-hoc multiple comparisons test. (G) GluA4 expression is not altered in 6 month-old Nptx2-/- mouse cortex. n = 4 for WT and n = 3 for Nptx2-/-. (H) Representative western blot images and quantification of GluA4 in forebrains of 6 month-old WT, hAPP and hAPP/Nptx2-/- mice. hAPP/Nptx2-/- mice show reduced GluA4 in brain. WT, n = 4; hAPP, n = 6; hAPP/Nptx2-/-, n = 4. **p<0.01 by nonparametric one way ANOVA with Tukey post hoc test. DOI: http://dx.doi.org/10.7554/eLife.23798.011CC BY · PubMed Central

Figure 3—figure supplement 1. NPTX2 expression in amyloidosis mouse model. Western blot assays show no significant change of NPTX2 expression in 6 month-old male APPswe/PS1∆E9 (hAPP) mouse brain when compared with wildtype (WT). n = 3. Two-tailed t test was performed. Data represent mean ± SEM. DOI: http://dx.doi.org/10.7554/eLife.23798.012CC BY · PubMed Central

Figure 3—figure supplement 2. Spontaneous sharp-wave ripples (SWRs) occur more frequently in hAPP/Nptx2-/- mice. (A–D) Example extracellular field recordings showing SWRs in unfiltered traces (i), with the boxed area filtered (100 to 250 Hz) to show an individual SWR (ii) and the corresponding wavelet transform of the unfiltered trace (iii) for WT (A), Nptx2-/- (B), hAPP (C), and hAPP/Nptx2-/- (D) mice. (E) The incidence of SWRs was significantly greater in hAPP/Nptx2-/- mice (WT, 0.55 ± 0.13 Hz, n = 12; Nptx2-/-, 0.28 ± 0.10 Hz, n = 10; hAPP, 0.59 ± 0.14 Hz, n = 17; hAPP/Nptx2-/-, 1.46 ± 0.32 Hz, n = 14; p=0.0010, One-way ANOVA; **, p<0.01 vs WT in post hoc Dunnet’s multiple comparisons test). (F) The peak frequency if SWRs was significantly reduced in hAPP/Nptx2-/- mice (WT, 198.7 ± 2.7 Hz; Nptx2-/-, 198.7 ± 3.4; hAPP, 192.6 ± 2.2 Hz; hAPP/Nptx2-/-, 188.2 ± 3.4 Hz; p=0.0384, One-way ANOVA; *, p<0.05 vs WT in post hoc Dunnets multiple comparisons test). (G,H) No significant differences were observed in either the SWR peak amplitude (G) (WT, 17.9 ± 2.3 µV; Nptx2-/-, 18.4 ± 4.3 µV; hAPP, 20.3 ± 4.4 µV; hAPP/Nptx2-/-, 24.6 ± 4.6 µV; p=0.6773, One-way ANOVA), or duration (H) (WT, 26.6 ± 1.4 ms; Nptx2-/-, 27.0 ± 1.3 ms; hAPP, 27.4 ± 1.1 ms; hAPP/Nptx2-/-, 29.1 ± 1.4 ms; p=0.5609, One-way ANOVA). DOI: http://dx.doi.org/10.7554/eLife.23798.013CC BY · PubMed Central

Figure 4. GluA4 levels are reduced in human postmortem AD brain. (A) Immunostaining of GluA4 demonstrates GluA4 is enriched on PV-IN in human cortex. Data were collected from four cases including occipital gyrus and parietal gyrus. (B and C) Representative western blot images (B) and quantification of GluA4 (C) in the frontopolar cortex (FPC), precuneus (PCU), middle frontal gyrus (MFG) and middle temporal gyrus (MTG) from controls and AD subjects. GluA4 is significantly down-regulated in PCU and MFG of AD individuals. FPC: control, n = 7; AD, n = 8. PCU: control, n = 15; AD, n = 19. MFG: control, n = 9; AD, n = 16. MTG: control, n = 10; AD, n = 18. *p<0.05 by two-tailed t test. Data represent mean ± SEM. (D) GluA4 levels correlate with NPTX2 in both control and AD group. Pearson correlation coefficient analysis was performed. (E and F) GluA4 expression did not correlate with NPTX2 in young adult brain. n = 10. Pearson correlation coefficient analysis was performed. (G and H) NPTX2 expression in young adult brain was higher than in aged controls. Young, n = 12; Aged, n = 15. **p<0.01 by two-tailed t test. Data represent mean ± SEM. DOI: http://dx.doi.org/10.7554/eLife.23798.014CC BY · PubMed Central

Figure 5. NPTX levels are reduced in CSF from individuals with clinically diagnosed AD. (A,B) Western blot assays of NPTX2, NPTX1 and NPTXR in lumbar cerebrospinal fluid (CSF) from age-matched controls and patients with clinically diagnosed AD. AD patients show reduced NPTX2, NPTX1 and NPTXR levels in CSF. Control, n = 36; AD, n = 30. (C) ELISA was developed to quantitate NPTX2 protein in CSF. NPTX2 assayed by ELISA corresponds closely with levels defined by WB. n = 64. Pearson correlation coefficient analysis was performed. (D) ELISA shows significant reduction of NPTX2 in CSF from patients with clinically diagnosed AD. Control, n = 36; AD, n = 28. (E) ELISA assay confirmed the reduction of NPTX2 in AD in second set of CSF sample. n = 36 for control, n = 30 for AD. (F) CSF NPTX2 levels are significantly reduced in individuals with mild cognitive impairment (MCI) compared with healthy controls. Control, n = 72; MCI, n = 17. (G–L) Receiver operating characteristic (ROC) curve analysis of CSF Aβ42 (G), tau (H), p-tau181 (I), NPTX2 (J), tau/NPTX2 (K) and p-tau/NPTX2 (L) as AD diagnostic biomarkers for distinguishing AD from control. Cut off values were determined by maximizing Youden index value. ROC analysis of tau/NPTX2 indicates its diagnostic power is superior to NPTX2 alone, Aß42, tau or p-tau. AUC: area under ROC curve. Control, n = 61–72; AD, n = 50–58. **p<0.01, ***p<0.001 by two-tailed t test. Data represent mean ± SEM. DOI: http://dx.doi.org/10.7554/eLife.23798.016CC BY · PubMed Central

Figure 5—figure supplement 1. Reduction of NPTXR levels in lumbar cerebrospinal fluid (CSF) from individuals with AD. (A) Representative western blot images show three major bands with human CSF samples by NPTXR antibody. (B) Patients with clinically diagnosed AD have reduced NPTXR levels in CSF compared with healthy controls. Control, n = 31; AD, n = 28. ***p<0.001 by two-tailed t test. Data represent mean ± SEM. DOI: http://dx.doi.org/10.7554/eLife.23798.019CC BY · PubMed Central

Figure 5—figure supplement 2. Detection of NPTX in human CSF. (A) NPTX2 and NPTX1 are detected in lumbar CSF of human subjects as a high molecular weight complex that is resolved into individual NPTXs with reducing reagent on SDS-PAGE. Arrows indicate monomer NPTX2 and NPTX1. BME: β-mercaptoethanol. (B) NPTX2 expression in CSF correlate with levels of CSF NPTX1 and NPTXR in individual samples. n = 66. Pearson correlation coefficient analysis was performed. DOI: http://dx.doi.org/10.7554/eLife.23798.020CC BY · PubMed Central

Figure 5—figure supplement 3. Development of NPTX2 ELISA assay. (A,B) Generation of mouse monoclonal NPTX2 antibody (A) and purification of NPTX2 protein (B) for ELISA assay. Western blots using mouse NPTX2 monoclonal antibody show a 50 kDa band in WT brain lysate that is absent in Nptx2-/- and Nptx1-/-; Nptx2-/-; Nptxr-/- (triple knockout, TKO) (A). DOI: http://dx.doi.org/10.7554/eLife.23798.021CC BY · PubMed Central

Figure 5—figure supplement 4. Reduction of NPTX levels in second set of CSF from individuals with AD. Representative western blot images and quantification of NPTX2, NPTX1 and NPTXR in second set of lumbar CSF from patients with clinically diagnosed AD. AD patients show reduced NPTX2, NPTX1 and NPTXR levels in CSF compared with healthy controls. Control, n = 36; AD, n = 30. *p<0.05, **p<0.01 by two-tailed t test. Data represent mean ± SEM. DOI: http://dx.doi.org/10.7554/eLife.23798.022CC BY · PubMed Central

Figure 5—figure supplement 5. Positive correlation of NPTXs with CSF tau and p-tau. (A–C) CSF NPTX2 levels correlate with CSF Tau (B) and p-Tau (C), but not with CSF Aβ42 (A) in AD patients. n = 49–51. Pearson correlation coefficient analysis was performed. (D–F) CSF NPTX1 levels correlate with CSF Tau (E) and p-Tau (F), but not with CSF Aβ42 (D) in AD patients. n = 49–51. Pearson correlation coefficient analysis was performed. (G–I) CSF NPTXR levels correlate with CSF Tau (H) and p-Tau (I), but not with CSF Aβ42 (G) in AD patients. n = 49–51. Pearson correlation coefficient analysis was performed. DOI: http://dx.doi.org/10.7554/eLife.23798.023CC BY · PubMed Central

Figure 6. NPTX2 expression correlates with cognitive performance and measures of hippocampal volume. (A) NPTX2 expression in CSF correlates with cognitive function assayed by DRS in AD group. n = 30. p=0.0093 by Pearson correlation coefficient analysis. DRS: dementia rating scale. (B–D) No correlation was observed between CSF Aβ42 (B), tau (C) or p-tau181 (D) with DRS in AD group. n = 28. (E–H) NPTX2 expression in CSF correlates with cognitive function assayed by WCST test (E), semantic verbal fluency test (F), VRT test (G) and CVLT test (H). n = 20–28. WCST: Wisconsin Card Sorting Task; AFV: Semantic Verbal Fluency Test (‘Animals’, ‘Fruits’, ‘Vegetables’); VRT: Visual Reproduction Test; CVLT: California Verbal Learning Test. Pearson correlation coefficient analysis was performed. (I) Representative images of human brain MRI imaging. (J) NPTX2 levels in CSF correlate with hippocampal occupancy. n = 25 AD subjects. HOC: hippocampal occupancy. DOI: http://dx.doi.org/10.7554/eLife.23798.024CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

“Mini-mental state”
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
[Japanese version of the Neuropsychiatric Inventory--a scoring system for neuropsychiatric disturbance in dementia patients].
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · PubMed · Cited by 21,012
Special Care Units and Traditional Care in Dementia: Relationship with Behavior, Cognition, Functional Status and Quality of Life - A Review
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J., & Wouters, E. (2015) · Gerontology · doi:10.1159/000430949 · Cited by 19,852
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. J. (2014) · Gerontology · doi:10.1159/000362720 · Cited by 19,007
The Brain's Default Network: Anatomy, Function, and Relevance to Disease
Buckner, R. L., Andrews‐Hanna, J. R., & Schacter, D. L. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1440.011 · Cited by 9,761
Basic principles of ROC analysis
Metz, C. E. (1978) · Seminars in Nuclear Medicine · doi:10.1016/s0001-2998(78)80014-2 · Cited by 6,122
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Boston Naming Test
Kaplan, E., Goodglass, H., Weıntraub, S., & Segal, O. (2001) · Medical Entomology and Zoology · Cited by 4,378
The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P. J., L. Whitwell, J., Ward, C., et al. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21049 · Cited by 4,347

Show all 91 references

Sorted by citations

Down syndrome
Antonarakis, S. E., Skotko, B. G., Rafii, M. S., Strydom, A., Pape, S. E., Bianchi, D. W., Sherman, S. L., & Reeves, R. H. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0143-7 · Cited by 964
Self-citation
Alzheimer's disease
López, J. A., González, H. M., & Léger, G. C. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804766-8.00013-3 · Cited by 887
Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer’s Disease Progression
Bai, B., Wang, X., Li, Y., Chen, P.-C., Yu, K., Dey, K. K., Yarbro, J. M., Han, X., Lutz, B. M., Rao, S., et al. (2020) · Neuron · doi:10.1016/j.neuron.2019.12.015 · Cited by 565
“(F) Consistent protein changes of 8 proteins in AD brain tissue and CSF.”
BackgroundInfluential
Synaptic degeneration in Alzheimer disease
Tzioras, M., McGeachan, R. I., Durrant, C. S., & Spires-Jones, T. L. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-022-00749-z · Cited by 504
Single-cell atlas reveals correlates of high cognitive function, dementia, and resilience to Alzheimer’s disease pathology
Mathys, H., Peng, Z., Boix, C. A., Victor, M. B., Leary, N., Babu, S., Abdelhady, G., Jiang, X., Ng, A. P., Ghafari, K., et al. (2023) · Cell · doi:10.1016/j.cell.2023.08.039 · Cited by 495
Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer’s disease
Higginbotham, L., Ping, L., Dammer, E. B., Duong, D. M., Zhou, M., Gearing, M., Hurst, C., Glass, J. D., Factor, S. A., Johnson, E. C. B., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz9360 · Cited by 367
Integrated Proteomics Reveals Brain-Based Cerebrospinal Fluid Biomarkers in Asymptomatic and Symptomatic Alzheimer’s Disease
Higginbotham, L., Ping, L., Dammer, E. B., Duong, D. M., Zhou, M., Gearing, M., Johnson, E. C. B., Hajjar, I., Lah, J. J., Levey, A. I., et al. (2019) · doi:10.1101/806752 · Cited by 367
Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery
Bai, B., Vanderwall, D., Li, Y., Wang, X., Poudel, S., Wang, H., Dey, K. K., Chen, P., Yang, K., & Peng, J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00474-z · Cited by 267
Optogenetic gamma stimulation rescues memory impairments in an Alzheimer’s disease mouse model
Etter, G., van der Veldt, S., Manseau, F., Zarrinkoub, I., Trillaud-Doppia, É., & Williams, S. (2019) · Nature Communications · doi:10.1038/s41467-019-13260-9 · Cited by 248
Declining levels of functionally specialized synaptic proteins in plasma neuronal exosomes with progression of Alzheimer's disease
Goetzl, E. J., Abner, E. L., Jicha, G. A., Kapogiannis, D., & Schwartz, J. B. (2018) · The FASEB Journal · doi:10.1096/fj.201700731r · Cited by 219
X‐linked adrenoleukodystrophy: Pathology, pathophysiology, diagnostic testing, newborn screening and therapies
Turk, B. R., Theda, C., Fatemi, A. S., & Moser, A. B. (2020) · International Journal of Developmental Neuroscience · doi:10.1002/jdn.10003 · Cited by 212
Astrocyte-Secreted Glypican 4 Regulates Release of Neuronal Pentraxin 1 from Axons to Induce Functional Synapse Formation
Farhy-Tselnicker, I., van Casteren, A. C. M., Lee, A., Chang, V. T., Aricescu, A. R., & Allen, N. J. (2017) · Neuron · doi:10.1016/j.neuron.2017.09.053 · Cited by 199
Fluid Biomarkers for Synaptic Dysfunction and Loss
Camporesi, E., Nilsson, J., Brinkmalm, A., Becker, B., Ashton, N. J., Blennow, K., & Zetterberg, H. (2020) · Biomarker Insights · doi:10.1177/1177271920950319 · Cited by 165
Shaping Synapses by the Neural Extracellular Matrix
Ferrer-Ferrer, M., & Dityatev, A. (2018) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2018.00040 · Cited by 169
Immediate and deferred epigenomic signatures of in vivo neuronal activation in mouse hippocampus
Fernandez-Albert, J., Lipinski, M., Lopez-Cascales, M. T., Rowley, M. J., Martin-Gonzalez, A. M., del Blanco, B., Corces, V. G., & Barco, A. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0476-2 · Cited by 166
Pros and Cons of Clinically Relevant Methods to Assess Pain in Rodents
Tappe‐Theodor, A., King, T. E., & Morgan, M. M. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.03.009 · Cited by 165
Targeting synapse function and loss for treatment of neurodegenerative diseases
Dejanovic, B., Sheng, M., & Hanson, J. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00823-1 · Cited by 177
Stimulus-dependent representational drift in primary visual cortex
Marks, T. D., & Goard, M. J. (2021) · Nature Communications · doi:10.1038/s41467-021-25436-3 · Cited by 185
The visual word form area (VWFA) is part of both language and attention circuitry
Chen, L., Wassermann, D., Abrams, D. A., Kochalka, J., Gallardo, G., & Menon, V. (2019) · Nature Communications · doi:10.1038/s41467-019-13634-z · Cited by 165
The neuronal pentraxin Nptx2 regulates complement activity and restrains microglia-mediated synapse loss in neurodegeneration
Zhou, J., Wade, S. D., Graykowski, D., Xiao, M.-F., Zhao, B., Giannini, L. A. A., Hanson, J. E., van Swieten, J. C., Sheng, M., Worley, P. F., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf0141 · Cited by 152
Self-citation
Potential role of chitinase‐3‐like protein 1 (CHI3L1/YKL‐40) in neurodegeneration and Alzheimer's disease
Connolly, K., Lehoux, M., O’Rourke, R., Assetta, B., Erdemir, G. A., Elias, J. A., Lee, C. G., & Huang, Y. A. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12612 · Cited by 149
Fast-spiking parvalbumin-positive interneurons in brain physiology and Alzheimer’s disease
Hijazi, S., Smit, A. B., & van Kesteren, R. E. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02168-y · Cited by 157
Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease
Galasko, D., Xiao, M., Xu, D., Smirnov, D., Salmon, D. P., Dewit, N., Vanbrabant, J., Jacobs, D., Vanderstichele, H., Vanmechelen, E., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.11.002 · Cited by 133
Self-citation
Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease
Libiger, O., Shaw, L. M., Watson, M. H., Nairn, A. C., Umaña, K. L., Biarnes, M. C., Canet‐Avilés, R. M., Jack, C. R., Breton, Y., Cortes, L., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12353 · Cited by 108
Quantitative proteomic profiling of cerebrospinal fluid to identify candidate biomarkers for Alzheimer’s disease
Sathe, G., Na, C. H., Renuse, S., Madugundu, A. K., Albert, M., Moghekar, A., & Pandey, A. (2019) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201800105 · Cited by 126
Input–output organization of the mouse claustrum
Zingg, B., Dong, H., Tao, H. W., & Zhang, L. I. (2018) · The Journal of Comparative Neurology · doi:10.1002/cne.24502 · Cited by 129
The functional organization of cortical feedback inputs to primary visual cortex
Marques, T., Nguyen, J. K., Fioreze, G. T., & Petreanu, L. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0135-z · Cited by 122
SpykeTorch: Efficient Simulation of Convolutional Spiking Neural Networks With at Most One Spike per Neuron
Mozafari, M., Ganjtabesh, ‎., Nowzari-Dalini, A., & Masquelier, T. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00625 · Cited by 125
Sub-second Dopamine and Serotonin Signaling in Human Striatum during Perceptual Decision-Making
Bang, D., Kishida, K. T., Lohrenz, T. M., White, J. P., Laxton, A. W., Tatter, S. B., Fleming, S. M., & Montague, P. R. (2020) · Neuron · doi:10.1016/j.neuron.2020.09.015 · Cited by 130
Excitatory-inhibitory imbalance in Alzheimer's disease and therapeutic significance
Varela, E. V., Etter, G., & Williams, S. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.04.010 · Cited by 122
The emerging role of chromatin remodelers in neurodevelopmental disorders: a developmental perspective
Mossink, B., Negwer, M., Schubert, D., & Nadif Kasri, N. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03714-5 · Cited by 114
Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration
Gómez de San José, N., Massa, F., Halbgebauer, S., Oeckl, P., Steinacker, P., & Otto, M. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-021-02411-2 · Cited by 112
An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead
Simrén, J., Ashton, N. J., Blennow, K., & Zetterberg, H. (2019) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2019.11.019 · Cited by 105
ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes
Soldan, A., Pettigrew, C. A., Fagan, A. M., Schindler, S. E., Moghekar, A., Fowler, C. J., Li, Q.-X., Collins, S. J., Carlsson, C. M., Asthana, S., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007248 · Cited by 107
N-myristoylation: from cell biology to translational medicine
Meng, Y. G., Song, Z., Ying, M., Zhu, H., He, Q., Yang, B., & Cao, J. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0388-4 · Cited by 101
Demystifying the extracellular matrix and its proteolytic remodeling in the brain: structural and functional insights
Krishnaswamy, V. R., Benbenishty, A., Blinder, P., & Sagi, I. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03182-6 · Cited by 96
Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia
van der Ende, E. L., Xiao, M., Xu, D., Poos, J. M., Panman, J. L., Jiskoot, L. C., Meeter, L. H., Dopper, E. G., Papma, J. M., Heller, C., et al. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-322493 · Cited by 94
Self-citation
Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease
Leuzy, A., Cullen, N. C., Mattsson, N., & Hansson, O. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000904 · Cited by 91
Comparison of SHANK3 deficiency in animal models: phenotypes, treatment strategies, and translational implications
Delling, J. P., & Boeckers, T. M. (2021) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-021-09397-8 · Cited by 104
Genetic regulatory subnetworks and key regulating genes in rat hippocampus perturbed by prenatal malnutrition: implications for major brain disorders
Chen, J., Zhao, X., Cui, L., He, G., Wang, X., Wang, F., Duan, S., He, L., Li, Q., Yu, X., et al. (2020) · Aging · doi:10.18632/aging.103150 · Cited by 91
Inhibitory Parvalbumin Basket Cell Activity is Selectively Reduced during Hippocampal Sharp Wave Ripples in a Mouse Model of Familial Alzheimer's Disease
Caccavano, A., Bozzelli, P. L., Forcelli, P. A., Pak, D. T. S., Wu, J., Conant, K. E., & Vicini, S. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.0425-20.2020 · Cited by 94
Vertebrate Sensory Ganglia: Common and Divergent Features of the Transcriptional Programs Generating Their Functional Specialization
Vermeiren, S., Bellefroid, E., & Desiderio, S. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.587699 · Cited by 82
Single organelle dynamics linked to 3D structure by correlative live‐cell imaging and 3D electron microscopy
Fermie, J., Liv, N., ten Brink, C., van Donselaar, E. G., Müller, W. H., Schieber, N. L., Schwab, Y., Gerritsen, H. C., & Klumperman, J. (2018) · Traffic · doi:10.1111/tra.12557 · Cited by 84
Evolving MRSA: High-level β-lactam resistance in Staphylococcus aureus is associated with RNA Polymerase alterations and fine tuning of gene expression
Panchal, V. V., Griffiths, C., Mosaei, H., Bilyk, B. L., Sutton, J. A. F., Carnell, O. T., HORNBY, D. P., Green, J. D., Hobbs, J. K., Kelley, W. L., et al. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008672 · Cited by 85
Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach
van Steenoven, I., Koel-Simmelink, M. J. A., Vergouw, L. J. M., Tijms, B. M., Piersma, S. R., Pham, T. V., Bridel, C., Ferri, G.-L., Cocco, C., Noli, B., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00388-2 · Cited by 83
Self-citation
Mitofusins: Disease Gatekeepers and Hubs in Mitochondrial Quality Control by E3 Ligases
Escobar‐Henriques, M., & Joaquim, M. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00517 · Cited by 85
Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
Nilsson, J., Gobom, J., Sjödin, S., Brinkmalm, G., Ashton, N. J., Svensson, J., Johansson, P., Portelius, E., Zetterberg, H., Blennow, K., et al. (2021) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12179 · Cited by 82
Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases
Nilsson, J., Binette, A. P., Palmqvist, S., Brum, W. S., Janelidze, S., Ashton, N. J., Spotorno, N., Stomrud, E., Gobom, J., Zetterberg, H., et al. (2024) · Brain · doi:10.1093/brain/awae032 · Cited by 90
Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer’s disease
Milà‐Alomà, M., Suárez‐Calvet, M., & Molinuevo, J. L. (2019) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286419888819 · Cited by 81
Impaired spike-gamma coupling of area CA3 fast-spiking interneurons as the earliest functional impairment in the AppNL-G-F mouse model of Alzheimer’s disease
Arroyo‐García, L. E., Isla, A. G., Andrade‐Talavera, Y., Balleza‐Tapia, H., Loera‐Valencia, R., Alvarez-Jimenez, L., Pizzirusso, G., Tambaro, S., Nilsson, P., & Fisahn, A. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01257-0 · Cited by 75
Deep proteomics identifies shared molecular pathway alterations in synapses of patients with schizophrenia and bipolar disorder and mouse model
Aryal, S., Bonanno, K., Song, B. J., Mani, D. R., Keshishian, H., Carr, S. A., Sheng, M., & Dejanovic, B. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112497 · Cited by 77
14-3-3 modulation of the inflammatory response
Munier, C. C., Ottmann, C., & Perry, M. W. D. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105236 · Cited by 79
Hippocampal network oscillations at the interplay between innate anxiety and learned fear
Çalışkan, G., & Stork, O. (2019) · Psychopharmacology · doi:10.1007/s00213-018-5109-z · Cited by 72
Neuroinflammation in Alzheimer’s disease: Pleiotropic roles for cytokines and neuronal pentraxins
Swanson, A., Wolf, T., Sitzmann, A., & Willette, A. A. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.02.015 · Cited by 72
Protein lifetimes in aged brains reveal a proteostatic adaptation linking physiological aging to neurodegeneration
Kluever, V., Russo, B., Mandad, S., Kumar, N. H., Alevra, M., Ori‬‬, A., Rizzoli, S. O., Urlaub, H., Schneider, A., & Fornasiero, E. F. (2022) · Science Advances · doi:10.1126/sciadv.abn4437 · Cited by 73
Evolving together, evolving apart: measuring the fitness of rhizobial bacteria in and out of symbiosis with leguminous plants
Burghardt, L. T. (2019) · New Phytologist · doi:10.1111/nph.16045 · Cited by 70
Eat, sleep, repeat – endocrine regulation of behavioural circadian rhythms
Koop, S., & Oster, H. (2021) · FEBS Journal · doi:10.1111/febs.16109 · Cited by 75
Novel CSF biomarkers in genetic frontotemporal dementia identified by proteomics
van der Ende, E. L., Meeter, L. H., Stingl, C., van Rooij, J. G. J., Stoop, M. P., Nijholt, D. A. T., Sanchez‐Valle, R., Graff, C., Öijerstedt, L., Grossman, M., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.745 · Cited by 65
Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer’s disease
Modeste, E. S., Ping, L., Watson, C. M., Duong, D. M., Dammer, E. B., Johnson, E. C. B., Roberts, B. R., Lah, J. J., Levey, A. I., & Seyfried, N. T. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00638-z · Cited by 66
Quantitative proteomic analysis of the frontal cortex in Alzheimer’s disease
Sathe, G. J., Albert, M., Darrow, J. A., Saito, A., Troncoso, J. C., Pandey, A., & Moghekar, A. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15116 · Cited by 65
Self-citation
A protein panel in cerebrospinal fluid for diagnostic and predictive assessment of Alzheimer’s disease
Haque, R., Watson, C. M., Liu, J., Carter, E. K., Duong, D. M., Lah, J. J., Wingo, A. P., Roberts, B. R., Johnson, E. C. B., Saykin, A. J., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adg4122 · Cited by 64
Chronic Microglial Activation in the GFAP-IL6 Mouse Contributes to Age-Dependent Cerebellar Volume Loss and Impairment in Motor Function
Gyengési, E., Rangel, A., Ullah, F., Liang, H., Niedermayer, G., Asgarov, R., Venigalla, M., Gunawardena, D., Karl, T., & Münch, G. W. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00303 · Cited by 64
HIV-1 Tat-Induced Astrocytic Extracellular Vesicle miR-7 Impairs Synaptic Architecture
Hu, G., Niu, F., Liao, K., Periyasamy, P., Sil, S., Liu, J., Dravid, S. M., & Buch, S. J. (2019) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09869-8 · Cited by 64
Defining the Teratoma as a Model for Multi-lineage Human Development
McDonald, D., Wu, Y., Dailamy, A., Tat, J., Parekh, U., Zhao, D., Hu, M. Y., Tipps, A. M. P., Zhang, K., & Mali, P. (2020) · Cell · doi:10.1016/j.cell.2020.10.018 · Cited by 60
Ca2+-Triggered Synaptic Vesicle Fusion Initiated by Release of Inhibition
Brünger, A. T., Leitz, J., Zhou, Q., Choi, U. B., & Lai, Y. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.03.004 · Cited by 61
NPTX2 promotes colorectal cancer growth and liver metastasis by the activation of the canonical Wnt/β-catenin pathway via FZD6
Xu, C., Tian, G.-A., Jiang, C., Xue, H., Kuerbanjiang, M., Sun, L., Gu, L., Zhou, H., Liu, Y., Zhang, Z., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1467-7 · Cited by 58
Fluid biomarkers in Alzheimer's disease
Simrén, J., Elmgren, A., Blennow, K., & Zetterberg, H. (2023) · Advances in Clinical Chemistry · doi:10.1016/bs.acc.2022.09.006 · Cited by 58
The Long Noncoding RNA Paupar Modulates PAX6 Regulatory Activities to Promote Alpha Cell Development and Function
Singer, R. A., Arnes, L., Cui, Y., Wang, J., Gao, Y., Guney, M. A., Burnum-Johnson, K., Rabadán, R., Ansong, C. K., Orr, G., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.09.013 · Cited by 58
A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia
van der Ende, E. L., Bron, E. E., Poos, J. M., Jiskoot, L. C., Panman, J. L., Papma, J. M., Meeter, L. H. H., Dopper, E. G. P., Wilke, C., Synofzik, M., et al. (2021) · Brain · doi:10.1093/brain/awab382 · Cited by 61
Cell cycle arrest determines adult neural stem cell ontogeny by an embryonic Notch-nonoscillatory Hey1 module
Harada, Y., Yamada, M., Imayoshi, I., Kageyama, R., Suzuki, Y., Kuniya, T., Furutachi, S., Kawaguchi, D., & Gotoh, Y. (2021) · Nature Communications · doi:10.1038/s41467-021-26605-0 · Cited by 56
Cerebrospinal Fluid Biomarkers of Synaptic Dysfunction are Altered in Parkinson's Disease and Related Disorders
Nilsson, J., Constantinescu, J., Nellgård, B., Jakobsson, P., Brum, W. S., Gobom, J., Forsgren, L., Dalla, K., Constantinescu, R., Zetterberg, H., et al. (2022) · Movement Disorders · doi:10.1002/mds.29287 · Cited by 59
A model of human neural networks reveals NPTX2 pathology in ALS and FTLD
Hruška-Plocháň, M., Wiersma, V. I., Betz, K. M., Mallona, I., Ronchi, S., Maniecka, Z., Hock, E., Tantardini, E., Laferrière, F., Sahadevan, S., et al. (2024) · Nature · doi:10.1038/s41586-024-07042-7 · Cited by 73
Invasive Insects: Management Methods Explored
McLaughlin, G. M., & Dearden, P. K. (2019) · Journal of Insect Science · doi:10.1093/jisesa/iez085 · Cited by 58
Structural basis for the tryptophan sensitivity of TnaC-mediated ribosome stalling
van der Stel, A., Gordon, E. R., Sengupta, A., Martínez, A. K., Klepacki, D., Perry, T. N., del Valle, A. H., Vázquez‐Laslop, N., Sachs, M. S., Cruz-Vera, L. R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25663-8 · Cited by 55
Precision Aging: Applying Precision Medicine to the Field of Cognitive Aging
Ryan, L., Hay, M., Huentelman, M. J., Duarte, A., Rundek, T., Levin, B. E., Soldan, A., Pettigrew, C. A., Mehl, M. R., & Barnes, C. A. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00128 · Cited by 55
Frontal cortex chitinase and pentraxin neuroinflammatory alterations during the progression of Alzheimer’s disease
Moreno‐Rodríguez, M., Perez, S. E., Nadeem, M., Malek‐Ahmadi, M. H., & Mufson, E. J. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-1723-x · Cited by 53
HOTAIR drives autophagy in midbrain dopaminergic neurons in the substantia nigra compacta in a mouse model of Parkinson’s disease by elevating NPTX2 via miR-221-3p binding
Lang, Y., Li, Y., Yu, H., Lin, L., Chen, X., Wang, S., & Zhang, H. (2020) · Aging · doi:10.18632/aging.103028 · Cited by 50
NPTX2 in Cerebrospinal Fluid Predicts the Progression From Normal Cognition to Mild Cognitive Impairment
Soldan, A., Oh, S., Ryu, T., Pettigrew, C. A., Zhu, Y., Moghekar, A., Xiao, M., Pontone, G. M., Albert, M., Na, C. H., et al. (2023) · Annals of Neurology · doi:10.1002/ana.26725 · Cited by 49
Self-citation
Adipose triglyceride lipase activity regulates cancer cell proliferation via AMP-kinase and mTOR signaling
Xie, H., Heier, C., Kien, B., Vesely, P. W., Tang, Z., Sexl, V., Schoiswohl, G., Strießnig-Bina, I., Höefler, G., Zechner, R., et al. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158737 · Cited by 48
The Role of Neuronal Pentraxin 2 (NP2) in Regulating Glutamatergic Signaling and Neuropathology
Chapman, G., Shanmugalingam, U., & Smith, P. D. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00575 · Cited by 48
The Novel Omega-6 Fatty Acid Docosapentaenoic Acid Positively Modulates Brain Innate Immune Response for Resolving Neuroinflammation at Early and Late Stages of Humanized APOE-Based Alzheimer's Disease Models
Ma, Q., Zhu, C., Morselli, M., Su, T., Pelligrini, M., Lu, Z., Jones, M. R., Denver, P., Castro, D., Gu, X., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.558036 · Cited by 48
A biomarker-authenticated model of schizophrenia implicating NPTX2 loss of function
Xiao, M.-F., Roh, S., Zhou, J., Chien, D. C.-C., Lucey, B. P., Craig, M. T., Hayes, L. N., Coughlin, J. M., Leweke, F. M., Jia, M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf6935 · Cited by 47
Self-citation
Precision Medicine and cardiac channelopathies: when dreams meet reality
Gnecchi, M., Sala, L., & Schwartz, P. J. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab007 · Cited by 45
Spatiotemporal transcriptomic maps of mouse intracerebral hemorrhage at single-cell resolution
Xiang, R., Wang, J., Chen, Z., Tao, J. Z., Peng, Q., Ding, R., Zhou, T., Tu, Z., Yang, T., Yang, T., et al. (2025) · Neuron · doi:10.1016/j.neuron.2025.04.026 · Cited by 51
LEAFY activity is post‐transcriptionally regulated by BLADE ON PETIOLE 2 and CULLIN 3 in Arabidopsis
Chahtane, H., Zhang, B., Norberg, M., Masson, M. L., Thévenon, E., Bakó, L., Benlloch, R., Holmlund, M., Parcy, F., Nilsson, O. R., et al. (2018) · New Phytologist · doi:10.1111/nph.15329 · Cited by 49
Resting-State Functional Connectivity Is Associated With Cerebrospinal Fluid Levels of the Synaptic Protein NPTX2 in Non-demented Older Adults
Soldan, A., Moghekar, A., Walker, K. A., Pettigrew, C. A., Hou, X., Lu, H., Miller, M. I., Alfini, A. J., Albert, M., Xu, D., et al. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00132 · Cited by 45
Self-citation
Cysteine oxidation and disulfide formation in the ribosomal exit tunnel
Schulte, L., Mao, J., Reitz, J., Sreeramulu, S., Kudlinzki, D., Hodirnau, V.-V., Meier‐Credo, J., Saxena, K., Buhr, F., Langer, J. D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19372-x · Cited by 47
Alterations of sleep oscillations in Alzheimer's disease: A potential role for GABAergic neurons in the cortex, hippocampus, and thalamus
Katsuki, F., Gerashchenko, D., & Brown, R. E. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.07.002 · Cited by 50
Data-Driven vs Consensus Diagnosis of MCI
Edmonds, E. C., Smirnov, D. S., Thomas, K. R., Graves, L. V., Bangen, K. J., Delano‐Wood, L., Galasko, D. R., Salmon, D. P., & Bondi, M. W. (2021) · Neurology · doi:10.1212/wnl.0000000000012600 · Cited by 45
Self-citation
APOE 𝜀4‐related blood–brain barrier breakdown is associated with microstructural abnormalities
Reas, E. T., Solders, S. K., Tsiknia, A. A., Triebswetter, C., Shen, Q., Rivera, C. S., Andrews, M., Alderson‐Myers, A., & Brewer, J. B. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14302 · Cited by 45
Self-citation
Identification of Neuronal Pentraxins as Synaptic Binding Partners of C1q and the Involvement of NP1 in Synaptic Pruning in Adult Mice
Kovács, R. Á., Vadászi, H., Bulyáki, É., Török, G., Tóth, V., Mátyás, D., Kun, J., Hunyadi-Gulyás, É., Fedor, F. Z., Csincsi, Á., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.599771 · Cited by 43
Unbiased classification of the elderly human brain proteome resolves distinct clinical and pathophysiological subtypes of cognitive impairment
Higginbotham, L. A., Carter, E. K., Dammer, E. B., Haque, R. U., Johnson, E. C. B., Duong, D. M., Yin, L., Jager, P. L. D., Bennett, D. A., Felsky, D., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106286 · Cited by 41
Guanosine monophosphate reductase 1 is a potential therapeutic target for Alzheimer’s disease
Liu, H., Luo, K., & Luo, D. (2018) · Scientific Reports · doi:10.1038/s41598-018-21256-6 · Cited by 42
Pathologically Decreased CSF Levels of Synaptic Marker NPTX2 in DLB Are Correlated with Levels of Alpha-Synuclein and VGF
Boiten, W., van Steenoven, I., Xiao, M.-F., Worley, P., Noli, B., Cocco, C., Ferri, G.-L., Lemstra, A., & Teunissen, C. (2020) · Cells · doi:10.3390/cells10010038 · Cited by 42
Self-citation
Dendritic processing of spontaneous neuronal sequences for single-trial learning
Haga, T., & Fukai, T. (2018) · Scientific Reports · doi:10.1038/s41598-018-33513-9 · Cited by 43
Overexpression of microRNA-301b accelerates hippocampal microglia activation and cognitive impairment in mice with depressive-like behavior through the NF-κB signaling pathway
Tang, C., Zhang, D., Yang, J., Liu, Q.-H., Wang, Y., & Wang, W. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1522-4 · Cited by 44
Neuroinflammation in CNS diseases: Molecular mechanisms and the therapeutic potential of plant derived bioactive molecules
Welcome, M. O. (2020) · PharmaNutrition · doi:10.1016/j.phanu.2020.100176 · Cited by 41
Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer’s disease-related inhibitory circuit dysfunction in adults with Down syndrome
Belbin, O., Xiao, M.-F., Xu, D., Carmona-Iragui, M., Pegueroles, J., Benejam, B., Videla, L., Fernández, S., Barroeta, I., Nuñez-Llaves, R., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00398-0 · Cited by 39
Self-citation
Monitoring synaptic pathology in Alzheimer’s disease through fluid and PET imaging biomarkers: a comprehensive review and future perspectives
Lista, S., Santos‐Lozano, A., Emanuele, E., Mercuri, N. B., Gabelle, A., López‐Ortiz, S., Martín-Hernández, J., Maisto, N., Imbimbo, C., Caraci, F., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02376-6 · Cited by 44
Structure of Myosin VI/Tom1 complex reveals a cargo recognition mode of Myosin VI for tethering
Hu, S., Guo, Y., Wang, Y., Li, Y., Fu, T., Zhou, Z., Wang, Y., Liu, J., & Pan, L. (2019) · Nature Communications · doi:10.1038/s41467-019-11481-6 · Cited by 40

Authors: Xiao, M.-F., Xu, D., Craig, M. T., Pelkey, K. A., Chien, C.-C., Shi, Y., Zhang, J., Resnick, S., Pletnikova, O., Salmon, D., Brewer, J., Edland, S., Wegiel, J., Tycko, B., Savonenko, A., Reeves, R. H., Troncoso, J. C., McBain, C. J., Galasko, D., & Worley, P. F.
Affiliations: Johns Hopkins University (US)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (US)
National Institute on Aging (US)
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, United States
University of California San Diego (US)
Institute for Basic Research, New York City, United States
Columbia University (US)
Corresponding author: Worley, Paul F
ORCID: Xiao, Mei-Fang
Xu, Desheng
Craig, Michael T
Pelkey, Kenneth A
Shi, Yang
Zhang, Juhong
Resnick, Susan
Salmon, David
Edland, Steven
Tycko, Benjamin
Savonenko, Alena
Reeves, Roger H
Troncoso, Juan C
McBain, Chris J
Worley, Paul F
Venue: eLife
Publisher: eLife Sciences Publications, Ltd
Published: 2017-03-23
Volume: 6
ISSN: 2050-084X (ISSN-L)
DOI: 10.7554/elife.23798
PMC: PMC5404919
OpenAlex: W2606988847
Cited by: 316
References: 91
Citations by year: 2026: 26 · 2025: 35 · 2024: 43 · 2023: 28 · 2022: 27 · 2021: 49 · 2020: 49 · 2019: 37 · 2018: 18 · 2017: 4
FWCI: 14.45
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (vor)
creativecommons.org/licenses/by/4.0/ (am)
creativecommons.org/licenses/by/4.0/ (tdm)
Locations: eLife (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
eScholarship (California Digital Library) (submittedVersion)
eScholarship (California Digital Library) (submittedVersion, cc-by)
Figshare (submittedVersion, cc-by)
Open Research Exeter (University of Exeter) (submittedVersion, cc-by)
Funders: LuMind Research Down Syndrome Foundation
National Institute on Aging (AG05131)
National Institute of Mental Health (P50 AG005146-27, MH100024, R35 NS-097966)
Alzheimer’s drug discovery foundation (20021106)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: NPTX2, Alzheimer's disease, cognitive impairment, GluA4, AMPA receptors, parvalbumin interneurons, fast-spiking interneurons, pyramidal neurons, hippocampus, cortical excitability, neural oscillations, amyloidosis, memory loss, cerebrospinal fluid biomarkers, hippocampal volume, synaptogenesis
MeSH terms: Pentraxins, Alzheimer Disease, Animals, C-Reactive Protein, Cerebral Cortex, Disease Models, Animal, Hippocampus, Humans, Nerve Tissue Proteins, Mice, Knockout, Mice, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

NPTX2 and cognitive dysfunction in Alzheimer’s Disease

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks